Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

Click here to read the article

Presented by Brian Slomovitz Director of Gynecologic Oncology  Co-Chair, Cancer Research Committee Mount Sinani Medical Center USA

Moderated by Leslie Randall Director of Gynecologic Oncology Clinical Research and Gynecologic Cancer Service Line Inova Schar Cancer Institute Inova Health System  USA

Supported in part by Pfizer | Genmab